Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustained Viral Suppression, and Exploratory Finite Treatment Data
Vir Biotechnology presented expanded Phase 2 SOLSTICE data showing 100% (28/28) of patients completing 96 weeks of elebsiran/tobevibart combination therapy achieved undetectable HDV RNA, with 89% showing improved or stable liver stiffness. In an exploratory finite-treatment analysis, all 10 patients who discontinued therapy after at least 96 weeks of undetectable virus achieved SVR12, with no viral rebound or ALT flares, suggesting potential curative intent for the regimen. The data accompany same-day topline Phase 3 ECLIPSE 1 results that met all study endpoints, supporting a planned mid-2027 U.S. FDA filing.
Key figures
- Drug Name
- elebsiran + tobevibart
- Phase Of Trial
- Phase 2 (SOLSTICE); Phase 3 ECLIPSE program
- Svr24
- 7
- Svr48
- 1
- Fda filing target
- mid-2027
- Week96 undetectable
- 28/28 (100%)
- Finite treatment patients
- 10/10 achieved SVR12
- Liver stiffness improved or stable
- 24/27 (89%)
- Cirrhotic patients in finite analysis
- 7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.